Unknown

Dataset Information

0

A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.


ABSTRACT: The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.

SUBMITTER: Zhang BZ 

PROVIDER: S-EPMC8118541 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8219092 | biostudies-literature
| S-EPMC7671939 | biostudies-literature
| S-EPMC7979827 | biostudies-literature
| S-EPMC10957958 | biostudies-literature
| S-EPMC8782996 | biostudies-literature
| S-EPMC8553838 | biostudies-literature
| S-EPMC5891362 | biostudies-literature
| S-EPMC9223271 | biostudies-literature
| S-EPMC8503606 | biostudies-literature
| S-EPMC10383203 | biostudies-literature